Celldex Therapeutics, Inc.

A Trio of Cancer Immunotherapy Innovators

By Seth Robey - June 14, 2013 | Tickers: BMY, CLDX, IMGN, RHHBY, SGEN

The cancer world has been abuzz after an exciting ASCO conference. Bristol-Myer's Squibb (NYSE: BMY) presented really promising updates for its PD-1 inhibitor nivolumab in late-stage melanoma, leading one Citigroup analyst to declare "the beginning of the end of cancer." With Merck and Roche (NASDAQOTH: RHHBY) also boasting PD-1 inhibitors we can only hope someone has a magic bullet. But is there space in this massive market for the more »
Good And Bad Breast Cancer Drugs

By Sherrie Stone - June 14, 2013 | Tickers: CLDX, GALE, RHHBY

With more than 230,000 women diagnosed with breast cancer in the U.S. annually – and Roche’s (NASDAQOTH: RHHBY) Herceptin producing annual sales of more than $5 billion – the potential for breast cancer drugs is enormous. While there are many companies developing drugs to treat the disease, there are two specifically with late-phase drugs that have been favorites in the market.

A breakthrough drug

Since the start of 2012 more »
A Promising Platform for Cancer Immunotherapy

By Seth Robey - June 10, 2013 | Tickers: BMY, CLDX, DNDN, MRK

A 2011 Nobel Prize in Physiology and Medicine is certainly impressive. Using a novel cancer treatment on yourself is both impressive and courageous. Dr. Ralph Steinman believed so enthusiastically in the cancer vaccines which he helped to develop that he used many of them to treat his own pancreatic cancer. Surviving for five additional years, Steinman was able to use his position on the Scientific Advisory Board of Celldex (NASDAQ: CLDX more »)
These 3 Biotech Stocks Look Interesting

By Shas Dey - April 30, 2013 | Tickers: ARIA, ARRY, CLDX

Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

Ariad Pharmaceuticals (NASDAQ: ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics (NASDAQ: CLDX) is exercising first-mover advantage by developing a novel but potent approach more »
Celldex Is Still a Buy

By Mohsin Saeed - March 26, 2013 | Tickers: AZN, CLDX, PFE

There has been a significant rally in the share price of Celldex (NASDAQ: CLDX) recently. The stock is still showing positive momentum due to strong data on its drug trials. This positive data makes the company an attractive target for big pharmaceutical players like Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). I believe that the positive momentum will continue and that Celldex is still a buy despite recent rallies.

Celldex more »
Noteworthy Upgrades on Friday: 2 to Buy & 2 to Sell

By Brian Nichols - March 9, 2013 | Tickers: CLDX, CBI, HL, THC

Celldex Therapeutics (NASDAQ: CLDX)

On Friday, a slew of upgrades came rolling in on shares of Celldex Therapeutics after the biotechnology stock lost significant value following earnings, which were on Thursday. That same day (Thursday) I wrote an article telling investors to “buy,” and I guess I wasn’t alone, as Roth Capital, Cantor Fitzgerald, and Jefferies all issued positive notes and bullish price targets on the same day.

The more »
Celldex May Soar in 2013

By Michael Meyer - January 10, 2013 | Tickers: CLDX, SGEN

With so many companies claiming to have found the miracle cure for all diseases, it can be a tough challenge to find the contenders instead of the pretenders. But there is one company that appears to be getting closer to find the illusive treatment for breast cancer. That company is Celldex Therapeutics (NASDAQ: CLDX).

Celldex Therapeutics is a biopharmaceutical company focused on the development, manufacture, and commercialization of novel therapeutics more »
3 Biotechs Moving Higher

By Cecil Sales - December 17, 2012 | Tickers: CTIX, CLDX, INFI

It has been a mixed year for the biotech industry with some moving up and some losing nearly 80% of their value. It’s a sector not exactly fraught with uncertainty, but has a big share of it nonetheless. For example, sometimes negative movement can be thanks to disappointing ends to FDA trials which are difficult to predict. After good trial data, often the risk profile declines as investors perceived more »
Biopharmaceutical Stocks: Possible Catalysts in December (Part I)

By Jorge Aura - December 4, 2012 | Tickers: ALXA, CLDX, DVAX, ZGNX

A good investment strategy is to anticipate future movements of biopharmaceutical companies. These companies are typically reevaluated weeks before presenting results of their studies or future meetings with the FDA.

The first company that present an important results of thier studies is Celldex Therapeutics (NASDAQ: CLDX). On Nov. 1, 2012 the company announced that present more mature data from the Emerge phase IIb study at the San Antonio Breast Cancer more »
Exclusive: Five Biotechs Picks from a Top Biotechnology Analyst

By Streetwise Reports - August 3, 2012 | Tickers: CELG, CLDX, IMGN, NLNK, ONTY

Five biotechs to consider

By George S. Mack, The Life Sciences Report

For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

Immunity is cancer's enemy

The complexity of the mammalian immune system is daunting for molecular biologists and drug developers, but incremental progress has brought biotech and biopharma to the point where small molecules and biologics are being developed with more »
4 Biotech Gems with Long-Term Bullish Potential

By Streetwise Reports - June 4, 2012 | Tickers: BTX, CLDX, CYBX, GERN, OMER

By George S. Mack, The Life Sciences Report

For more than 22 years WBB Securities Founder and Managing Partner Stephen Brozak has been in the securities business where he has done everything from sales and management to investment banking and performing as a sellside analyst. Armed with an MBA from Columbia University and his experience as retired Lieutenant Colonel from the U.S. Marine Corps, Brozak is goal-driven with an more »